Perform Another (Advanced) Search

1.  Newly Approved Drug Therapies (13) Intron A (Interferon alfa-2b, recombinant), Schering-Plough,
...subjects with malignant melanoma. The product has previously received U.S. marketing clearance for treating hairy cell leukemia, AIDS-related Kaposi's sarcoma, condylomata acuminata, and chronic hepatitis B and C. Intron ...
View Page

2.  Newly Approved Drug Therapies (351) Intron A (interferon alfa-2b, recombinant), Schering-Plough,
...clearance in the U.S. for the treatment of chronic hepatitis B, chronic hepatitis C, hairy cell leukemia, AIDS related Kaposi's sarcoma, condylomata acuminata (venereal warts), and as adjuvant therapy for ...
View Page

3.  Newly Approved Drug Therapies (249) Intron A (interferon alfa-2b, recombinant), Schering-Plough,
...use by the FDA for chronic viral hepatitis B, chronic viral hepatitis C, malignant melanoma, hairy cell leukemia, AIDS-related Kaposi’s sarcoma and condylomata acuminata (venereal warts). INTRON A is marketed ...
View Page

4.  CenterWatch: New Medical Therapies in Disease Category (203), Non-Hodgkin's Lymphoma
...Hodgkin’s lymphoma. Nipent is currently approved as a single-agent treatment for patients with hairy cell leukemia. Results showed the combination therapy demonstrated activity with acceptable toxicity in subjects with relapsed ...
View Page

5.  CenterWatch: New Medical Therapies in Disease Category (402), Cancer/Tumors
...or mixed responses. A long term follow-up study of Nipent in 180 subjects with hairy cell leukemia demonstrated a response rate of 98%. Data showed that 83% of subjects achieved a ...
View Page

6.  CenterWatch: New Medical Therapies in Disease Category (771),
...or mixed responses. A long term follow-up study of Nipent in 180 subjects with hairy cell leukemia demonstrated a response rate of 98%. Data showed that 83% of subjects achieved a ...
View Page

7.  CenterWatch: New Medical Therapies in Disease Category (92), Leukemia
...or mixed responses. A long term follow-up study of Nipent in 180 subjects with hairy cell leukemia demonstrated a response rate of 98%. Data showed that 83% of subjects achieved a ...
View Page